Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients-Reference-Cited by-同舟云学术

Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients

Published:2008-04 Issue:2 Volume:69 Page:166-179
ISSN:0011-393X
Container-title:Current Therapeutic Research
language:en
Short-container-title:Current Therapeutic Research

Author:

Piotrowska Ewa,Jakóbkiewicz-Banecka Joanna,Tylki-Szymanska Anna,Liberek Anna,Maryniak Agnieszka,Malinowska Marcelina,Czartoryska Barbara,Puk Ewa,Kloska Anna,Liberek Tomasz,Baranska Sylwia,Wegrzyn Alicja,Wegrzyn Grzegorz

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference30 articles.

1. The mucopolysaccharidoses;Neufeld,2001

2. A general model for genetic regulation of turn-over of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses;Wegrzyn;Med Hypotheses,2004

3. Enzyme-replacement therapy in mucopolysaccharidosis I;Kakkis;N Engl J Med,2001

4. Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase);Wraith;J Pediatr,2004

5. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years;Sifuentes;Mol Genet Metab,2007

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond;BioDrugs;2024-08-23

2. Substrate reduction therapy in aDrosophila melanogastermodel of Sanfilippo syndrome;2023-03-28

3. Current and new therapies for mucopolysaccharidoses;Pediatrics & Neonatology;2023-02

4. In vitro substrate reduction, chaperone and immunomodulation treatments reduce heparan sulfate in mucolipidosis III human fibroblasts;Genetics and Molecular Biology;2023

5. Hopes and disappointments related to the use of flavonoids in therapeutical approaches;Modulation of Oxidative Stress;2023